Hengrui Medicine announced that its subsidiaries have received approval from China's National Medical Products Administration for clinical trials of three drugs. These include SHR-3821 for advanced solid tumors, Adebelimumab injection (already approved in 2023), and Rilafuvirt-alpha injection (approved January 2026). Separately, Xiangcai Co. has had its merger review with Dazhihui resumed by the Shanghai Stock Exchange after a previous suspension due to outdated financial data. AI
RANK_REASON The cluster contains multiple significant corporate announcements including drug trial approvals and a merger review resumption. [lever_c_demoted from significant: ic=1 ai=0.1]
- Adebelimumab injection
- Hengrui Medicine
- National Medical Products Administration
- Rilafuvirt-alpha injection
- Shanghai Dazhihui Co., Ltd.
- Shanghai Shengdiya Pharmaceutical Co., Ltd.
- Shanghai Stock Exchange
- SHR-3821
- Suzhou Shengdiya Biopharmaceutical Co., Ltd.
- Xiangcai Co.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
